Phillip Gambel

Array ( [id] => 8865627 [patent_doc_number] => 20130149330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'PHARMACEUTICAL COMPOSITIONS AND METHODS OF BLOCKING BACILLUS ANTHRACIS' [patent_app_type] => utility [patent_app_number] => 13/759224 [patent_app_country] => US [patent_app_date] => 2013-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7915 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13759224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8903652 [patent_doc_number] => 20130171155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-04 [patent_title] => 'Inhibitors Of Complement Activation' [patent_app_type] => utility [patent_app_number] => 13/759743 [patent_app_country] => US [patent_app_date] => 2013-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 20519 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13759743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9529957 [patent_doc_number] => 08753826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-17 [patent_title] => 'Methods of detecting factor D with anti-factor D antibodies' [patent_app_type] => utility [patent_app_number] => 13/759613 [patent_app_country] => US [patent_app_date] => 2013-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 17730 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13759613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10882691 [patent_doc_number] => 08907072 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-09 [patent_title] => 'Nucleic acids encoding antibody 137-26 which binds C5 and C5a' [patent_app_type] => utility [patent_app_number] => 13/759687 [patent_app_country] => US [patent_app_date] => 2013-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9438 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13759687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11408974 [patent_doc_number] => 09556266 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Methods of treating sickle cell disease with anti-P-selectin antibodies' [patent_app_type] => utility [patent_app_number] => 13/757405 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11963 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 220 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13757405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10406676 [patent_doc_number] => 20150291686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-15 [patent_title] => 'AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/369370 [patent_app_country] => US [patent_app_date] => 2012-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 7612 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14369370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9661730 [patent_doc_number] => 08808701 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-19 [patent_title] => 'Methods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies' [patent_app_type] => utility [patent_app_number] => 13/720685 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 53 [patent_no_of_words] => 43274 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13720685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134388 [patent_doc_number] => 20130295102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P' [patent_app_type] => utility [patent_app_number] => 13/716526 [patent_app_country] => US [patent_app_date] => 2012-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 49184 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13716526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9015564 [patent_doc_number] => 20130230528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'METHODS FOR DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISORDERS MEDIATED BY CD40 SIGNALING' [patent_app_type] => utility [patent_app_number] => 13/717175 [patent_app_country] => US [patent_app_date] => 2012-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 44977 [patent_no_of_claims] => 115 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13717175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10863930 [patent_doc_number] => 08889628 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-18 [patent_title] => 'Soluble tandem selectin glycoprotein ligand molecules' [patent_app_type] => utility [patent_app_number] => 13/688187 [patent_app_country] => US [patent_app_date] => 2012-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 11 [patent_no_of_words] => 8864 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13688187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10912235 [patent_doc_number] => 20140315252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE' [patent_app_type] => utility [patent_app_number] => 14/360048 [patent_app_country] => US [patent_app_date] => 2012-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 21221 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14360048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8930511 [patent_doc_number] => RE044389 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2013-07-23 [patent_title] => 'Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies' [patent_app_type] => reissue [patent_app_number] => 13/653597 [patent_app_country] => US [patent_app_date] => 2012-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 23749 [patent_no_of_claims] => 81 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13653597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10220284 [patent_doc_number] => 20150105278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'METHODS OR RISK ASSESSMENT OF PML AND RELATED APPARATUS' [patent_app_type] => utility [patent_app_number] => 14/352402 [patent_app_country] => US [patent_app_date] => 2012-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 47400 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14352402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10869820 [patent_doc_number] => 08895010 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-25 [patent_title] => 'Antibody polypeptides that antagonize CD40L' [patent_app_type] => utility [patent_app_number] => 13/650493 [patent_app_country] => US [patent_app_date] => 2012-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 36 [patent_no_of_words] => 47752 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13650493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10614891 [patent_doc_number] => 09334326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-10 [patent_title] => 'Antibody that binds domain 2 of ICAM-1 and methods of treatment' [patent_app_type] => utility [patent_app_number] => 14/428274 [patent_app_country] => US [patent_app_date] => 2012-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 14369 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14428274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8841106 [patent_doc_number] => 20130136734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-30 [patent_title] => 'ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND RELATED THERAPIES' [patent_app_type] => utility [patent_app_number] => 13/648808 [patent_app_country] => US [patent_app_date] => 2012-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 13662 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13648808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12509304 [patent_doc_number] => 10000553 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-19 [patent_title] => CD40L-specific TN3-derived scaffolds and methods of use thereof [patent_app_type] => utility [patent_app_number] => 14/347016 [patent_app_country] => US [patent_app_date] => 2012-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 49541 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14347016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8707527 [patent_doc_number] => 20130064816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-14 [patent_title] => 'TNF-alpha ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE' [patent_app_type] => utility [patent_app_number] => 13/645332 [patent_app_country] => US [patent_app_date] => 2012-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 17869 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13645332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9685309 [patent_doc_number] => 20140242072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-28 [patent_title] => 'ANTI-ICAM-1 ANTIBODIES TO TREAT MULTIPLE-MYELOMA RELATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/347636 [patent_app_country] => US [patent_app_date] => 2012-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11724 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14347636 [rel_patent_id] =>[rel_patent_doc_number] =>)